{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T17:49:27Z","timestamp":1777571367769,"version":"3.51.4"},"reference-count":36,"publisher":"American Society of Consultant Pharmacists","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["sr care pharm"],"published-print":{"date-parts":[[2022,7,1]]},"abstract":"<jats:p><jats:bold>Objectives<\/jats:bold>To evaluate the efficacy and safety of megestrol for off-label use in older patients with weight loss.<jats:bold>Design<\/jats:bold>Retrospective, nonblinded cohort study.<jats:bold>Setting<\/jats:bold>Upstate University Hospital is a 420-bed facility and academic medical center with a level 1 trauma center. Upstate Community Hospital is a 314-bed acute care\/hospital\/ambulatory care center and long-term care hospital that also provides teaching services.<jats:bold>Participants<\/jats:bold>Patients 65 years of age and older without malignancy or acquired immunodeficiency syndrome who were initiated and continued megestrol therapy at the Upstate University hospitals for at least two weeks were included. Of the 1,290 patients initially screened, 16 patients on megestrol were evaluated. An age- and gender-matched control group of 16 patients was utilized for comparison of changes in weight and other variables.<jats:bold>Interventions<\/jats:bold>Patients in the megestrol group have received daily doses of megestrol between 160 mg to 800 mg for an average duration of 19 days. Patients in the control group had no history or current use of megestrol utilization.<jats:bold>Main Outcome Measurements<\/jats:bold>The primary outcome was an increase in weight. Secondary outcome measures included albumin and thromboembolic events. Changes in weight and albumin were also compared with the control group.<jats:bold>Results<\/jats:bold>At a mean duration of 19 days, there was no significant difference in weight gain (0.95 kg, OR = 1.33 [95% CI -1.615-3.527]). Albumin decreased by (0.4 g\/dL OR = 0.916 [95% CI 0.12-0.78]) and none of the patients developed a thromboembolic event.<jats:bold>Conclusion<\/jats:bold>In older hospitalized patients, megestrol did not increase weight, and did not improve albumin. No thromboembolic events were observed, but this may be because of a limited duration of observation of therapy and the routine use of anticoagulation prophylaxis in the inpatient setting.<\/jats:p>","DOI":"10.4140\/tcp.n.2022.284","type":"journal-article","created":{"date-parts":[[2022,6,26]],"date-time":"2022-06-26T04:30:56Z","timestamp":1656217856000},"page":"284-292","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of Megestrol in the Hospitalized Older Person"],"prefix":"10.4140","volume":"37","author":[{"given":"Nicole C.","family":"Cheung","sequence":"first","affiliation":[{"name":"1Florida Agricultural and Mechanical University, Tallahassee, Florida."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Noviasky","sequence":"additional","affiliation":[{"name":"2Upstate Community Hospital, Department of Pharmacy, Syracuse, New York."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly R.","family":"Ulen","sequence":"additional","affiliation":[{"name":"3Upstate Community Hospital, Syracuse, New York."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon A.","family":"Brangman","sequence":"additional","affiliation":[{"name":"4SUNY Upstate Medical University Department of Geriatrics, Syracuse, New York."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2625","reference":[{"key":"ref1","article-title":"The Graying of America: More Older Adults Than Kids by 2035.","year":"2018"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.clnu.2008.06.013","article-title":"Cachexia: a new definition.","volume":"27","year":"2008","journal-title":"Clin Nutr."},{"issue":"3","key":"ref3","first-page":"52","article-title":"Diagnosing malnutrition in the elderly.","volume":"26","year":"2001","journal-title":"Nurse Pract."},{"issue":"2","key":"ref4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3390\/nu8020069","article-title":"Anorexia of aging: risk factors, consequences, and potential treatments.","volume":"8","year":"2016","journal-title":"Nutrients."},{"key":"ref5","first-page":"20e","article-title":"Unintentional weight loss.","volume-title":"Harrison\u2019s Principles of Internal Medicine,","year":"2018"},{"issue":"4","key":"ref6","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/jcsm.12192","article-title":"Anorexia of ageing: a key component in the pathogenesis of both sarcopenia and cachexia.","volume":"8","year":"2017","journal-title":"J Cachexia Sarcopenia Muscle."},{"issue":"2","key":"ref7","first-page":"97","article-title":"Polypharmacy among the elderly.","volume":"9","year":"2018","journal-title":"J Midlife Health."},{"key":"ref8","article-title":"Rapid geriatric assessment.","volume-title":"An Issue of Clinics in Geriatric Medicine.","year":"2017"},{"issue":"1","key":"ref9","article-title":"Appetite stimulants in long term care: a literature review.","volume":"11","year":"2009","journal-title":"J Adv Nurs."},{"key":"ref10","first-page":"950960","article-title":"American Geriatrics Society identifies another five things that healthcare providers and patients should question.","volume":"62","year":"2014","journal-title":"J Am Geriatr Soc."},{"issue":"2","key":"ref11","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1200\/JCO.2002.20.2.567","article-title":"Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study.","volume":"20","year":"2002","journal-title":"J Clin Oncol."},{"issue":"6","key":"ref12","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1503\/cmaj.1031527","article-title":"An approach to the management of unintentional weight loss in elderly people.","volume":"172","year":"2005","journal-title":"CMAJ."},{"issue":"3","key":"ref13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/1060028018802816","article-title":"Efficacy and safety of appetite-stimulating medications in the inpatient setting.","volume":"53","year":"2019","journal-title":"Ann Pharmacother."},{"key":"ref14","year":"2012"},{"issue":"4","key":"ref15","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2147\/nano.2006.1.4.411","article-title":"Megestrol acetate in cachexia and anorexia.","volume":"1","year":"2006","journal-title":"Int J Nanomedicine."},{"key":"ref16","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/j.1532-5415.2005.53307.x","article-title":"The effects of megestrol acetate suspension for elderly patients with reduced appetite after hospitalization: a phase ii randomized clinical trial.","volume":"53","year":"2005","journal-title":"JAGS."},{"key":"ref17","first-page":"485","article-title":"Improvement in quality-of-life measures and stimulation of weight gain after treatment with megestrol acetate oral suspension in geriatric cachexia: results of a double-blind, placebo-controlled study.","volume":"49","year":"2000","journal-title":"J Am Geriatr Soc."},{"key":"ref18","article-title":"Are the therapeutic strategies in anorexia of ageing effective on nutritional status? A systematic review with meta-analysis.","year":"2019","journal-title":"J Hum Nutr Diet."},{"issue":"9","key":"ref19","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1007\/s11255-019-02245-8","article-title":"The effects of megestrol acetate on nutrition, inflammation and quality of life in elderly haemodialysis patients.","volume":"51","year":"2019","journal-title":"Int Urol Nephrol."},{"key":"ref20","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S1525-8610(04)70369-2","article-title":"Incidence of deep-venous thrombosis in nursing home residents using megestrol acetate.","volume":"4","year":"2003","journal-title":"J Am Med Dir Assoc."},{"issue":"4","key":"ref21","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/jgs.15767","article-title":"American Geriatrics Society 2019 updated AGS Beers Criteria for potentially inappropriate medication use in older adults.","volume":"67","year":"2019","journal-title":"J Am Geriatr Soc."},{"issue":"4","key":"ref22","first-page":"272","article-title":"Malnutrition: laboratory markers vs nutritional assessment.","volume":"4","year":"2016","journal-title":"Gastroenterol Rep (Oxf)."},{"issue":"4","key":"ref23","doi-asserted-by":"crossref","first-page":"239","DOI":"10.12788\/jhm.3088","article-title":"Things we do for no reason: prealbumin testing to diagnose malnutrition in the hospitalized patient.","volume":"14","year":"2019","journal-title":"J Hosp Med."},{"issue":"3","key":"ref24","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1177\/0148607112440285","article-title":"Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition).","volume":"36","year":"2012","journal-title":"J Parenter Enteral Nutr."},{"issue":"9","key":"ref25","first-page":"1023","article-title":"Serum albumin and prealbumin in calorically restricted, nondiseased individuals: a systematic review.","volume":"128","year":"2015","journal-title":"Am J Med."},{"key":"ref26","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0163-7258(94)90066-3","article-title":"Age, environmental factors and drug metabolism.","volume":"61","year":"1994","journal-title":"Pharmacol Ther."},{"issue":"3","key":"ref27","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1023\/A:1008291825695","article-title":"Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: a randomised placebo-controlled trial.","volume":"8","year":"1997","journal-title":"Ann Oncol."},{"issue":"4","key":"ref28","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1200\/JCO.1993.11.4.762","article-title":"Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and\/or cachexia.","volume":"11","year":"1993","journal-title":"J Clin Oncol."},{"issue":"13","key":"ref29","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/jnci\/82.13.1127","article-title":"Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia.","volume":"82","year":"1990","journal-title":"J Natl Cancer Inst."},{"issue":"4","key":"ref30","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00000421-199808000-00006","article-title":"Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia.","volume":"21","year":"1998","journal-title":"Am J Clin Oncol."},{"issue":"9","key":"ref31","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1161\/01.ATV.0000087141.05044.1F","article-title":"Differential effects of oral and transdermal estrogen\/progesterone regimens on sensitivity to activated protein c among postmenopausal women: a randomized trial.","volume":"23","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"9","key":"ref32","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1111\/j.1538-7836.2004.00894.x","article-title":"Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives.","volume":"2","year":"2004","journal-title":"J Thromb Haemost."},{"issue":"10","key":"ref33","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1177\/2047487318774847","article-title":"Association between progestin-only contraceptive use and cardiometabolic outcomes: a systematic review and meta-analysis.","volume":"25","year":"2018","journal-title":"Eur J Prev Cardiol."},{"issue":"6","key":"ref34","first-page":"e5004","article-title":"Megestrol acetate induced paradoxical embolism in a sickle cell disease patient.","volume":"11","year":"2019","journal-title":"Cureus."},{"key":"ref35","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/oxfordjournals.aje.a117094","article-title":"Physical activity in older middle-aged men and reduced risk of stroke: the Honolulu Heart Program.","volume":"139","journal-title":"Am J Epidemiol."},{"issue":"12","key":"ref36","first-page":"e67","article-title":"Heart disease and stroke statistics\u20142018 update: a report from the American Heart Association.","volume":"137","year":"2018","journal-title":"Circulation."}],"container-title":["The Senior Care Pharmacist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ascp\/tscp\/2022\/00000037\/00000007\/art00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T19:18:48Z","timestamp":1700767128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.4140\/TCP.n.2022.284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,1]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7,1]]}},"alternative-id":["2639-9636(20220701)37:7L.284;1-"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2022.284","relation":{},"ISSN":["2639-9636"],"issn-type":[{"value":"2639-9636","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7,1]]}}}